Oncolytic Viral Therapy to Potentiate Immune Checkpoint Blockade in Immunologically Cold Brain Tumors
Abstract
In year three of the projects period we have made significant advances in the mouse studies, the multi-omics profiling of clinical and murine specimens, and bioinformatics analysis of the resulting data. We have completed the projected prospective collections of blood and CSF from the PNOC MV-NIS clinical trial and met our projects targets. The genomics profiling of these tissues, according to our SOW, is also complete. Likewise, we have completed profiling all archival frozen-tumor and blood specimens from the PNOC trial, as well as all archival and prospective frozen tumor tissues from UCSF. The resulting data have been preprocessed, subjected to quality control, and are the subject of ongoing analysis. We have made significant progress in our mouse studies, having performed the control and monotherapy arms for the Toca-511 virus and MV-NIS oncolytic virus treatment. The mouse studies included single-cell profiling of tumor tissue from responders and non-responders, as well as RNA seq of murine blood specimens, which are complete. Preprocessing of the murine data and comparison to the human data is ongoing. Combination therapy arms of the murine studies are ongoing.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jul 01, 2022
- Accession Number
- AD1190537
Entities
People
- Aaron Diaz
Organizations
- University of California, San Francisco